Labcorp Holdings (LH) Earnings Analysis
Labcorp Holdings (LH) next reports earnings on 2026-07-30, consensus EPS 4.79 USD. Last quarter (2026-04-30) it beat with EPS 4.25 USD vs 4.11 USD est (+3.4%). It has beaten estimates in 6/6 recent quarters (100%). Trailing P/E 24.75.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does LH next report earnings?
| Next earnings date | 2026-07-30 |
|---|---|
| Consensus EPS estimate | 4.79 USD |
| Revenue estimate | 3.71B |
LH earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-30 | 4.25 USD | 4.11 USD | +3.4% | Beat |
| 2026-02-17 | 4.07 USD | 3.95 USD | +3% | Beat |
| 2025-07-24 | 4.35 USD | 4.17 USD | +4.3% | Beat |
| 2025-02-06 | 3.45 USD | 3.39 USD | +1.8% | Beat |
| 2024-10-24 | 3.5 USD | 3.47 USD | +0.9% | Beat |
| 2024-08-01 | 3.94 USD | 3.78 USD | +4.2% | Beat |
Beat rate: 6/6 (100%) over reported quarters with consensus data.
LH valuation and analyst view
| Trailing P/E | 24.75 |
|---|---|
| Trailing EPS | 11.44 USD |
| Price / book | 2.65 |
| Dividend yield | 1.02% |
| Market cap | 22.95B |
| Analyst consensus | Buy (26 buy / 9 hold / 0 sell) |
| Avg price target | 334 USD |
Related research pages
Frequently asked questions
When is Labcorp Holdings (LH)'s next earnings date?
Labcorp Holdings is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 4.79 USD and revenue estimate of 3.71B.
Did LH beat earnings last quarter?
In its 2026-04-30 report, LH posted EPS of 4.25 USD versus a 4.11 USD estimate — a beat of 3.4%.
What is LH's earnings track record?
Over the last 6 reported quarters with consensus data, LH beat estimates 6 times (100%).
What is LH's current P/E ratio and EPS?
LH trades at a trailing P/E of 24.75 on trailing EPS of 11.439854191980558 USD.
What do analysts rate LH?
Analyst consensus is "Buy" across 35 ratings (0 strong buy, 26 buy, 9 hold, 0 sell, 0 strong sell). Average 12-month price target: 334 USD.